Amanda Kabage, our Research Program Manager, spoke at a public FDA hearing to discuss the clinical evidence for safety and efficacy of FMT treatment for recurrent C. difficile patients under the FDA’s enforcement discretion policy. View Here.


© 2024 Regents of the University of Minnesota. All rights reserved. The University of Minnesota is an equal opportunity educator and employer. Privacy Statement